PT2094694E - Derivados de quiniclidina de ácido (hetero arilcicloheptanocarboxílico como antagonistas do receptor muscarínico - Google Patents

Derivados de quiniclidina de ácido (hetero arilcicloheptanocarboxílico como antagonistas do receptor muscarínico Download PDF

Info

Publication number: PT2094694E
Authority: PT; Portugal
Prior art keywords: alkyl; oxy; carbonyl; azoniabicyclo; halogen
Prior art date: 2006-11-14

Application number

PT07824574T

Other languages

English (en)

Portuguese (pt)

Inventor

Rhonan Ford

Andrew Mather

Antonio Mete

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-14

Filing date

2007-11-13

Publication date

2011-03-17

2007-11-13 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2011-03-17 Publication of PT2094694E publication Critical patent/PT2094694E/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Tropical Medicine & Parasitology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
AIDS & HIV (AREA)
Transplantation (AREA)

PT07824574T 2006-11-14 2007-11-13 Derivados de quiniclidina de ácido (hetero arilcicloheptanocarboxílico como antagonistas do receptor muscarínico PT2094694E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86566706P	2006-11-14	2006-11-14
US86938406P	2006-12-11	2006-12-11

Publications (1)

Publication Number	Publication Date
PT2094694E true PT2094694E (pt)	2011-03-17

Family

ID=39048793

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT07824574T PT2094694E (pt)	2006-11-14	2007-11-13	Derivados de quiniclidina de ácido (hetero arilcicloheptanocarboxílico como antagonistas do receptor muscarínico

Country Status (29)

Country	Link
US (2)	US8207193B2 (2)
EP (2)	EP2256117A1 (2)
JP (1)	JP4904402B2 (2)
KR (1)	KR20090078828A (2)
AR (1)	AR063804A1 (2)
AT (1)	ATE496916T1 (2)
AU (1)	AU2007321019B2 (2)
BR (1)	BRPI0718750A2 (2)
CA (1)	CA2669326A1 (2)
CL (1)	CL2007003260A1 (2)
CO (1)	CO6160312A2 (2)
CY (1)	CY1111351T1 (2)
DE (1)	DE602007012300D1 (2)
DK (1)	DK2094694T3 (2)
EC (1)	ECSP099338A (2)
HR (1)	HRP20110178T1 (2)
IL (1)	IL198314A (2)
MX (1)	MX2009004780A (2)
MY (1)	MY148392A (2)
NO (1)	NO20092224L (2)
NZ (1)	NZ576679A (2)
PE (1)	PE20081164A1 (2)
PL (1)	PL2094694T3 (2)
PT (1)	PT2094694E (2)
RS (1)	RS51650B (2)
RU (1)	RU2456286C2 (2)
SA (1)	SA07280616B1 (2)
TW (1)	TW200825084A (2)
WO (1)	WO2008059245A1 (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2007275561B2 (en) *	2006-07-21	2013-12-19	Mars, Incorporated	Improvement of arginase levels/activity
TW200825084A (en)	2006-11-14	2008-06-16	Astrazeneca Ab	New compounds 521
EA017627B1 (ru) *	2008-05-13	2013-01-30	Астразенека Аб	Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
GB0808709D0 (en) *	2008-05-13	2008-06-18	Astrazeneca Ab	New combination 295
BRPI0912657A2 (pt) *	2008-05-13	2016-01-26	Astrazeneca Ab	produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor
GB0808708D0 (en) *	2008-05-13	2008-06-18	Astrazeneca Ab	New compounds 274
GB0811099D0 (en) *	2008-06-17	2008-07-23	Astrazeneca Ab	New combination 376
KR20110022611A (ko) *	2008-06-20	2011-03-07	아스트라제네카 아베	베타２－아드레날린수용체 활성의 조절을 위한, ４－히드록시－２－옥소－２,３－디히드로－１,３－벤조티아졸－７－일 화합물을 포함하는 제약 조성물
WO2010008341A1 (en) *	2008-07-16	2010-01-21	Astrazeneca Ab	A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
GB0814729D0 (en) *	2008-08-12	2008-09-17	Argenta Discovery Ltd	New combination
EP2206712A1 (en) *	2008-12-23	2010-07-14	CHIESI FARMACEUTICI S.p.A.	"Alkaloid aminoester derivatives and medicinal composition thereof"
TW201036957A (en)	2009-02-20	2010-10-16	Astrazeneca Ab	Novel salt 628
TWI546537B (zh) *	2009-05-19	2016-08-21	維維亞生技公司	提供針對血液腫瘤之體外個人化藥物測試之方法
EP2585457B1 (en) *	2010-06-22	2015-07-22	Chiesi Farmaceutici S.p.A.	Alkaloid aminoester derivatives and medicinal composition thereof
JP2011195593A (ja) *	2011-06-30	2011-10-06	Astrazeneca Ab	ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
EP3363462A1 (en)	2012-04-30	2018-08-22	Biothera, Inc.	Compositions and methods for beta-glucan immunotherapy
TW201517906A (zh)	2013-07-25	2015-05-16	Almirall Sa	含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) *	2014-09-26	2016-05-16	阿爾米雷爾有限公司	具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL62140C (2)	1942-12-16
DE2104179C3 (de)	1971-01-29	1980-10-02	Knoll Ag, 6700 Ludwigshafen	exo-2-Phenyl-bicyclo- [2,2,1] -heptan-2- (N-methylpiperidol-4)-carbonsäureester und dessen Salze, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel
FR2155927A1 (en)	1971-10-15	1973-05-25	Synthelabo	1-phenylcyclo hexane carboxylic acid esters - with antispasmodic and anticholinergic activity
FR2168881A1 (en)	1972-01-25	1973-09-07	Synthelabo	Tropanol 1-phenylcycloalkane carboxylic ester salts - spasmolytics and cholinergics
FR2208649A1 (en)	1972-12-01	1974-06-28	Synthelabo	1-(2-Thienyl)cycloalkane carboxylic ester salts - with spasmolytic and anticholinergic activity
GB8334494D0 (en)	1983-12-24	1984-02-01	Tanabe Seiyaku Co	Carbostyril derivatives
IL77458A (en)	1985-01-14	1990-07-26	Eisai Co Ltd	Cephem derivatives,their production and antibacterial compositions containing them and certain novel intermediates therefor
GR1001529B (el)	1990-09-07	1994-03-31	Elmuquimica Farm Sl	Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9003057D0 (sv)	1990-09-26	1990-09-26	Astra Ab	New process
AU1578692A (en)	1991-03-07	1992-10-06	G.D. Searle & Co.	New meso-azacyclic aromatic acid amides and esters as novel serotonergic agents
NO2005012I1 (no) *	1994-12-28	2005-06-06	Debio Rech Pharma Sa	Triptorelin og farmasoytisk akseptable salter derav
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
DE69720965T2 (de)	1996-02-13	2004-02-05	Astrazeneca Ab	Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en)	1996-03-05	2000-03-27	Zeneca Ltd	4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
JP2000515881A (ja)	1996-07-29	2000-11-28	フアーマシア・アンド・アツプジヨン・アー・ベー	アリールシクロアルカンカルボン酸エステル、その使用、薬剤組成物および調製
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
US6613795B2 (en)	1996-11-11	2003-09-02	Christian Noe	Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
CN100391942C (zh)	1996-11-11	2008-06-04	索佛特克两合公司	对映异构纯的碱性芳基-环烷基-羟基羧酸酯,其制备方法及其在药品中的应用
GB9714249D0 (en)	1997-07-08	1997-09-10	Angiogene Pharm Ltd	Vascular damaging agents
GB9900334D0 (en)	1999-01-07	1999-02-24	Angiogene Pharm Ltd	Tricylic vascular damaging agents
GB9900752D0 (en)	1999-01-15	1999-03-03	Angiogene Pharm Ltd	Benzimidazole vascular damaging agents
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
AU2001258628A1 (en)	2000-05-31	2001-12-11	Astrazeneca Ab	Indole derivatives with vascular damaging activity
GB0015876D0 (en)	2000-06-28	2000-08-23	Novartis Ag	Organic compounds
MXPA02012903A (es)	2000-07-07	2004-07-30	Angiogene Pharm Ltd	Derivados de colquinol como inhibidores de angiogenesis.
MXPA02012905A (es)	2000-07-07	2004-07-30	Angiogene Pharm Ltd	Derivados de colquinol como agentes de dano vascular..
NZ526580A (en) *	2000-12-22	2005-04-29	Almirall Prodesfarma Ag	Quinuclidine carbamate derivatives and their use as M3 antagonists
DE60121813T2 (de)	2000-12-28	2007-09-20	Almirall Ag	Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten
ES2296923T3 (es)	2001-03-22	2008-05-01	Glaxo Group Limited	Derivados formanilidas como agonistas del adrenorreceptor beta2.
JP2004532874A (ja) *	2001-04-03	2004-10-28	アリックスセラピューティクス	抗コリン作用性化合物および使用法
KR100831534B1 (ko)	2001-04-30	2008-05-22	글락소 그룹 리미티드	17.알파 위치에 시클릭 에스테르기를 지닌 항염증성의안드로스탄의 17.베타.-카르보티오에이트 에스테르 유도체
US20030229058A1 (en)	2001-11-13	2003-12-11	Moran Edmund J.	Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en)	2001-11-13	2006-02-21	Theravance Inc	Aryl aniline beta2 adrenergic receptor agonists
DE10216333A1 (de)	2002-04-13	2003-10-30	Boehringer Ingelheim Pharma	Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ES2206021B1 (es)	2002-04-16	2005-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de pirrolidinio.
ES2302938T3 (es)	2002-10-11	2008-08-01	Pfizer Inc.	Derivados de indol como agonistas beta-2.
US7056916B2 (en)	2002-11-15	2006-06-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Medicaments for the treatment of chronic obstructive pulmonary disease
AR044134A1 (es)	2003-05-02	2005-08-24	Novartis Ag	Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
PE20050231A1 (es)	2003-06-24	2005-05-20	Novartis Ag	Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
US20090246281A1 (en)	2003-11-03	2009-10-01	Norton Healthcare Ltd.	Soft steroid compositions for use in dry powder inhalers
US20080027094A1 (en)	2004-08-30	2008-01-31	Ono Pharmaceutical Co., Ltd.	Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient
EP1797040A1 (en)	2004-09-29	2007-06-20	Ranbaxy Laboratories Limited	Muscarinic receptor antagonists
US20090093485A1 (en)	2004-10-29	2009-04-09	Astrazeneca Ab	Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases
GB0424284D0 (en) *	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0428416D0 (en)	2004-12-24	2005-02-02	Novartis Ag	Organic compounds
TW200722418A (en)	2005-04-20	2007-06-16	Astrazeneca Ab	Novel compounds
CN101233107A (zh)	2005-08-01	2008-07-30	阿斯利康(瑞典)有限公司	作为趋化因子受体调节剂用于治疗呼吸系统疾病的新哌啶衍生物
TW200738635A (en)	2005-08-02	2007-10-16	Astrazeneca Ab	New salt
JP2009504624A (ja)	2005-08-08	2009-02-05	アージェンタディスカバリーリミテッド	ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用
GB0516313D0 (en)	2005-08-08	2005-09-14	Argenta Discovery Ltd	Azole derivatives and their uses
TW200738658A (en)	2005-08-09	2007-10-16	Astrazeneca Ab	Novel compounds
TW200738659A (en)	2005-08-29	2007-10-16	Astrazeneca Ab	Novel compounds
US20090182033A1 (en)	2005-12-16	2009-07-16	Argenta Discovery Ltd.	Cyclic Amine Derivatives and Their Uses
EP2013172A4 (en)	2006-04-24	2010-08-04	Astrazeneca Ab	NEW ALKYLESTERS FROM CYCLIC AMINO ALCOHOLS WITH MUSCARIN M3 RECEPTORANTAGONOSTIC ACTIVITY FOR THE TREATMENT OF CHRONIC BRONCHIA SUPPRESSION, ASTHMA OR OVERACTIVE HARNBASE
CA2657639A1 (en)	2006-07-19	2008-01-24	Astrazeneca Ab	Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
WO2008017827A2 (en)	2006-08-08	2008-02-14	Argenta Discovery Limited	Azole and thiazole derivatives and their uses
GB0702384D0 (en)	2007-02-07	2007-03-21	Argenta Discovery Ltd	Chemical compounds
WO2008023157A1 (en)	2006-08-21	2008-02-28	Argenta Discovery Limited	Nitrogen containing heterocyclic compounds useful as m3-receptor modulators
EP1894568A1 (en)	2006-08-31	2008-03-05	Novartis AG	Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
TW200825084A (en)	2006-11-14	2008-06-16	Astrazeneca Ab	New compounds 521
WO2008059239A1 (en)	2006-11-14	2008-05-22	Astrazeneca Ab	Novel compounds 514
ATE555111T1 (de)	2006-12-19	2012-05-15	Astrazeneca Ab	Chinuclidinol-derivate als muscarinrezeptor- antagonisten
WO2008075006A1 (en)	2006-12-19	2008-06-26	Astrazeneca Ab	Piperldinum compounds for treatment of obstructive pulmonary diseases ( copd)
TW200833670A (en)	2006-12-20	2008-08-16	Astrazeneca Ab	Novel compounds 569
WO2008096093A1 (en)	2007-02-06	2008-08-14	Argenta Discovery Ltd.	Oxazole and thiazole derivatives and their uses
WO2008096094A1 (en)	2007-02-06	2008-08-14	Argenta Discovery Ltd.	Bicyclor[2.2.1]hept-7-ylamine derivatives as muscarinic m3 receptor modulators
NZ578475A (en)	2007-02-07	2011-05-27	Pulmagen Therapeutics Synergy	Napadisylate salt of a muscarinic m3 antagonist
GB0702382D0 (en)	2007-02-07	2007-03-21	Argenta Discovery Ltd	New salt
GB0702416D0 (en)	2007-02-07	2007-03-21	Argenta Discovery Ltd	New combination
GB0702413D0 (en)	2007-02-07	2007-03-21	Argenta Discovery Ltd	New chemical compounds
WO2008096129A1 (en)	2007-02-07	2008-08-14	Argenta Discovery Ltd	Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702414D0 (en)	2007-02-07	2007-03-21	Argenta Discovery Ltd	Oxazole and thiazole derivatives and their uses 2
GB0702385D0 (en)	2007-02-07	2007-03-21	Argenta Discovery Ltd	New combination
GB0702456D0 (en)	2007-02-08	2007-03-21	Astrazeneca Ab	New combination
GB0702457D0 (en)	2007-02-08	2007-03-21	Astrazeneca Ab	New combination 666
EP2121688A1 (en)	2007-02-15	2009-11-25	Argenta Discovery Ltd	Heterocyclic derivatives as m3 muscarinic receptors
GB0704000D0 (en)	2007-03-01	2007-04-11	Astrazeneca Ab	Salts 670
WO2008149110A1 (en)	2007-06-08	2008-12-11	Argenta Discovery Limited	Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
WO2008149053A1 (en)	2007-06-08	2008-12-11	Argenta Discovery Ltd.	Bicycl0 [2. 2. 1] he pt- 2-ylamine derivates and their use
WO2009098455A1 (en)	2008-02-06	2009-08-13	Astrazeneca Ab	2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease
WO2009098453A1 (en)	2008-02-06	2009-08-13	Astrazeneca Ab	Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists
PL2242759T3 (pl)	2008-02-06	2013-06-28	Astrazeneca Ab	Związki
BRPI0912657A2 (pt) *	2008-05-13	2016-01-26	Astrazeneca Ab	produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor
GB0808708D0 (en)	2008-05-13	2008-06-18	Astrazeneca Ab	New compounds 274
EA017627B1 (ru)	2008-05-13	2013-01-30	Астразенека Аб	Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
GB0808707D0 (en)	2008-05-13	2008-06-18	Argenta Discovery Ltd	New compounds 275
GB0808709D0 (en)	2008-05-13	2008-06-18	Astrazeneca Ab	New combination 295
GB0811100D0 (en)	2008-06-17	2008-07-23	Astrazeneca Ab	New combination
WO2009153536A1 (en)	2008-06-17	2009-12-23	Argenta Discovery Limited	1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists
GB0811099D0 (en)	2008-06-17	2008-07-23	Astrazeneca Ab	New combination 376
WO2010015792A1 (en)	2008-08-06	2010-02-11	Argenta Discovery Limited	Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
CA2733449A1 (en)	2008-08-12	2010-02-18	Astrazeneca Ab	2-hydroxy-ethanesulfonate salt
GB0814729D0 (en)	2008-08-12	2008-09-17	Argenta Discovery Ltd	New combination
GB0814728D0 (en)	2008-08-12	2008-09-17	Argenta Discovery Ltd	New combination
WO2010018352A1 (en)	2008-08-12	2010-02-18	Argenta Discovery Limited	Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated

2007
- 2007-11-02 TW TW096141387A patent/TW200825084A/zh unknown
- 2007-11-12 SA SA07280616A patent/SA07280616B1/ar unknown
- 2007-11-13 HR HR20110178T patent/HRP20110178T1/hr unknown
- 2007-11-13 DE DE602007012300T patent/DE602007012300D1/de active Active
- 2007-11-13 PT PT07824574T patent/PT2094694E/pt unknown
- 2007-11-13 RU RU2009115829/04A patent/RU2456286C2/ru not_active IP Right Cessation
- 2007-11-13 KR KR1020097009772A patent/KR20090078828A/ko not_active Ceased
- 2007-11-13 CA CA002669326A patent/CA2669326A1/en not_active Abandoned
- 2007-11-13 AR ARP070105051A patent/AR063804A1/es not_active Application Discontinuation
- 2007-11-13 WO PCT/GB2007/004350 patent/WO2008059245A1/en not_active Ceased
- 2007-11-13 US US12/514,509 patent/US8207193B2/en not_active Expired - Fee Related
- 2007-11-13 PL PL07824574T patent/PL2094694T3/pl unknown
- 2007-11-13 EP EP10175910A patent/EP2256117A1/en not_active Withdrawn
- 2007-11-13 RS RS20110126A patent/RS51650B/sr unknown
- 2007-11-13 PE PE2007001564A patent/PE20081164A1/es not_active Application Discontinuation
- 2007-11-13 BR BRPI0718750-5A patent/BRPI0718750A2/pt not_active IP Right Cessation
- 2007-11-13 MX MX2009004780A patent/MX2009004780A/es active IP Right Grant
- 2007-11-13 JP JP2009536788A patent/JP4904402B2/ja not_active Expired - Fee Related
- 2007-11-13 AT AT07824574T patent/ATE496916T1/de active
- 2007-11-13 DK DK07824574.3T patent/DK2094694T3/da active
- 2007-11-13 CL CL200703260A patent/CL2007003260A1/es unknown
- 2007-11-13 MY MYPI20091925A patent/MY148392A/en unknown
- 2007-11-13 AU AU2007321019A patent/AU2007321019B2/en not_active Ceased
- 2007-11-13 EP EP07824574A patent/EP2094694B1/en active Active
- 2007-11-13 NZ NZ576679A patent/NZ576679A/en not_active IP Right Cessation
2009
- 2009-04-23 IL IL198314A patent/IL198314A/en not_active IP Right Cessation
- 2009-04-24 CO CO09041752A patent/CO6160312A2/es unknown
- 2009-05-15 EC EC2009009338A patent/ECSP099338A/es unknown
- 2009-06-09 NO NO20092224A patent/NO20092224L/no not_active Application Discontinuation
2011
- 2011-03-22 CY CY20111100315T patent/CY1111351T1/el unknown
2012
- 2012-05-15 US US13/471,912 patent/US20130005695A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20130005695A1 (en)	2013-01-03
MX2009004780A (es)	2009-05-21
WO2008059245A1 (en)	2008-05-22
IL198314A (en)	2013-06-27
RU2456286C2 (ru)	2012-07-20
NZ576679A (en)	2011-04-29
PL2094694T3 (pl)	2011-05-31
RU2009115829A (ru)	2010-12-20
JP4904402B2 (ja)	2012-03-28
EP2256117A1 (en)	2010-12-01
RS51650B (sr)	2011-10-31
CA2669326A1 (en)	2008-05-22
KR20090078828A (ko)	2009-07-20
SA07280616B1 (ar)	2010-11-22
AU2007321019B2 (en)	2011-04-21
PE20081164A1 (es)	2008-10-31
NO20092224L (no)	2009-06-22
JP2010509391A (ja)	2010-03-25
ECSP099338A (es)	2009-06-30
AR063804A1 (es)	2009-02-18
CL2007003260A1 (es)	2008-05-23
IL198314A0 (en)	2010-02-17
US20100029713A1 (en)	2010-02-04
CO6160312A2 (es)	2010-05-20
HRP20110178T1 (hr)	2011-04-30
MY148392A (en)	2013-04-15
ATE496916T1 (de)	2011-02-15
CY1111351T1 (el)	2015-08-05
EP2094694B1 (en)	2011-01-26
HK1134091A1 (en)	2010-04-16
TW200825084A (en)	2008-06-16
DK2094694T3 (da)	2011-04-04
US8207193B2 (en)	2012-06-26
DE602007012300D1 (de)	2011-03-10
EP2094694A1 (en)	2009-09-02
AU2007321019A1 (en)	2008-05-22
BRPI0718750A2 (pt)	2013-12-03

Publication	Publication Date	Title
PT2094694E (pt)	2011-03-17	Derivados de quiniclidina de ácido (hetero arilcicloheptanocarboxílico como antagonistas do receptor muscarínico
ES2385681T3 (es)	2012-07-30	Derivados de quinuclidinol como antagonistas de receptores muscarínicos
WO2009139709A1 (en)	2009-11-19	Quinuclidine derivatives and their use as muscarinic receptor antagonists for the treatment of asthma and chronic obstructive pulmonary disease (copd)
EA017627B1 (ru)	2013-01-30	Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
US20090233965A1 (en)	2009-09-17	Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder
WO2009139710A1 (en)	2009-11-19	Quinuclidine derivatives and their use as muscarinic receptor antagonists
WO2008059239A1 (en)	2008-05-22	Novel compounds 514
US20090042942A1 (en)	2009-02-12	Muscarinic Receptor Antagonists
WO2008075006A1 (en)	2008-06-26	Piperldinum compounds for treatment of obstructive pulmonary diseases ( copd)
CN101490003A (zh)	2009-07-22	具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物
CN101535306B (zh)	2012-09-12	作为毒蕈碱受体拮抗剂的（杂）芳基环庚基甲酸的奎宁环衍生物
ES2357988T3 (es)	2011-05-04	Derivados de quiniclidina de ácido(hetero)arilcicloheptanocarboxílico como antagonistas del receptor muscarínico.
WO2010018352A1 (en)	2010-02-18	Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
HK1134091B (en)	2011-08-19	Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists
HK1148001A (en)	2011-08-26	Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists
CN101163673A (zh)	2008-04-16	新的毒蕈碱性受体拮抗剂